Lactobacillus paracasei L9 improves colitis by expanding butyrate-producing bacteria that inhibit the IL-6/STAT3 signaling pathway
Lactobacillus paracasei L9 improves colitis by expanding butyrate-producing bacteria that inhibit the IL-6/STAT3 signaling pathway
复制标题
副干酪乳杆菌 L9 通过扩大抑制 IL-6/STAT3 信号通路的丁酸产生细菌来改善结肠炎
DOI：
10.1039/d1fo02077c
复制
发表时间：
2021-09-07
期刊：
影响因子：
6.1
通讯作者：
Yu, Zhengquan
中科院分区：
文献类型：
--
作者：
Deng, Min;Wu, Xi;Yu, Zhengquan
炎症性肠病（IBD）是一种目前无法治愈的慢性肠道炎症。越来越多的证据表明，补充益生菌可以改善IBD的症状。因此，寻找新的有效的IBD治疗菌株具有重要的科学意义。据报道，从健康百岁老人肠道中鉴定出的益生菌副干酪乳杆菌L9（L9）能够调节宿主免疫力，起到抗过敏作用。在这里，我们证明了L9通过扩大产丁酸细菌的丰度来改变实验性结肠炎的病理表型。丁酸钠在实验性结肠炎中的口服给药概括了L9抗炎表型。从机制上讲，丁酸钠通过抑制结肠炎中的IL-6/STAT 3信号通路来改善炎症反应。总体而言，这些发现表明，L9通过增加产生丁酸盐的丁酸盐产生细菌菌株的丰度来抑制DSS诱导的结肠炎发展，从而抑制IL-6/STAT 3信号传导途径，为IBD缓解的有希望的治疗靶点提供了新的见解。
Inflammatory bowel disease (IBD) is a chronic intestinal inflammation that is currently incurable. Increasing evidence indicates that supplementation with probiotics could improve the symptoms of IBD. It is scientifically significant to identify novel and valid strains for treating IBD. It has been reported that the probiotic Lactobacillus paracasei L9 (L9), which is identified from the gut of healthy centenarians, can modulate host immunity and plays an anti-allergic role. Here, we demonstrated that L9 alleviates the pathological phenotypes of experimental colitis by expanding the abundance of butyrate-producing bacteria. Oral administration of sodium butyrate in experimental colitis recapitulates the L9 anti-inflammatory phenotypes. Mechanistically, sodium butyrate ameliorated the inflammatory responses by inhibiting the IL-6/STAT3 signaling pathway in colitis. Overall, these findings demonstrated that L9 alleviates the DSS-induced colitis development by enhancing the abundance of butyrate-producing bacterial strains that produce butyrate to suppress the IL-6/STAT3 signaling pathway, providing new insight into a promising therapeutic target for the remission of IBD.